Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CCR1 | P32246 | 1/20 | 0.78 |
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16772254 | 0.91 | CCR1 (0.83) | CYP1A2CCR1FERMT2KDM4ELMNA | |
| SCHEMBL31038417 | 0.91 | CCR1 (0.83) | CYP1A2CCR1FERMT2KDM4ELMNA | |
| SCHEMBL8738060 | 0.91 | CYP1A2 (1.00) | CYP1A2CCR1FERMT2KDM4ELMNA | |
| SCHEMBL19841699 | 0.90 | CCR1 (0.86) | CYP1A2CCR1FERMT2KDM4ELMNA | |
| SCHEMBL15923067 | 0.89 | CCR1 (0.84) | CYP1A2CCR1FERMT2KDM4ELMNA | |
| SCHEMBL14668240 | 0.89 | CCR1 (0.84) | CYP1A2CCR1FERMT2KDM4ELMNA | |
| SCHEMBL15923405 | 0.89 | CCR1 (0.84) | CYP1A2CCR1FERMT2KDM4ELMNA | |
| SCHEMBL13496090 | 0.88 | CYP1A2 (0.77) | CYP1A2CCR1FERMT2KDM4ELMNA | |
| SCHEMBL1147093 | 0.87 | CYP1A2 (0.81) | CYP1A2CCR1FERMT2KDM4ELMNA | |
| SCHEMBL23340252 | 0.87 | CYP1A2 (0.85) | CYP1A2CCR1FERMT2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022250971-A1 | SMALL MOLECULE INHIBITORS OF AUTOPHAGY AND HISTONE DEACTYLASES AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-2822936-B1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | MCLEAN HOSPITAL CORP (US) | 2021-09-08 | — | — | EP | disclosed |
| WO-2021087077-A1 | SMALL MOLECULE INHIBITORS OF AUTOPHAGY AND HISTONE DEACTYLASES AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20160168099-A1 | NOVEL BISAMINOQUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM AND THEIR USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-06-16 | — | — | US | disclosed |
| EP-2379505-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | Designmedix, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-7968539-B2 | reversed chloroquines; to treat chloroquine resistant/sensitive malaria parasites; N'-(7-Chloro-quinolin-4-yl)-N-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-N-methyl-propane-1,3-diamine | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100216727-A1 | Carbohydrate-metallocene-antimalarial conjugates | ADVANCED APPLIED PHYSICS SOLUTIONS (CA) | 2010-08-26 | — | — | US | disclosed |
| WO-2010065932-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | DESIGNMEDIX, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090291923-A1 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | JOHNS HOPKINS UNIVERSOTY (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291923-A1 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | JOHNS HOPKINS UNIVERSOTY (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2007067333-A2 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | JOHNS HOPKINS UNIVERSITY (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168099-A1 | NOVEL BISAMINOQUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM AND THEIR USE | UACA, SQSTM1, ATG7 | CYP1A2 3178/4885CCR1 3605/4885FERMT2 4433/4885 |
| US-20100216727-A1 | Carbohydrate-metallocene-antimalarial conjugates | G6PD, SLC40A1, SLC2A8 | CYP1A2 747/4885CCR1 588/4885FERMT2 2043/4885 |
| US-20090291923-A1 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | HCCS, XPO5, DHX15 | CYP1A2 596/4885CCR1 3839/4885FERMT2 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.